Longeveron (NASDAQ:LGVN) Issues Earnings Results, Misses Expectations By $0.01 EPS

Longeveron (NASDAQ:LGVN) issued its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01), FiscalAI reports. Longeveron had a negative net margin of 1,977.59% and a negative return on equity of 222.38%. The business had revenue of $0.29 million during the quarter, compared to analyst estimates of $0.33 million.

Here are the key takeaways from Longeveron’s conference call:

• ELPIS II topline results for laromestrocel in hypoplastic left heart syndrome are expected in September, with database lock planned for August 31. Management believes favorable results could support a BLA pathway, potentially including priority review.
• Longeveron ended the quarter with $10.1 million in cash and expects existing funds to support operations only through the fourth quarter of 2026. Net loss rose 22% year over year to $6.1 million, while revenue declined 10% to $0.3 million.
• Management said it has made progress on manufacturing and CMC preparations and is exploring partnerships with major pharmaceutical companies, particularly if the HLHS data are positive. A partner could provide additional capital, commercial infrastructure, and global reach.
• Laromestrocel was selected as a finalist in the XPRIZE Healthspan competition from more than 600 applicants and received a $1 million award, adding external validation to the age-related frailty program and potentially supporting future longevity partnerships.
• The company is preparing a potential 2027 Phase II trial in pediatric dilated cardiomyopathy, supported by an already-effective IND and possible eligibility for a priority review voucher, but the program remains preclinical-to-early clinical planning and requires further funding.

Longeveron Trading Up 7.8%

Shares of NASDAQ LGVN traded up $0.05 during mid-day trading on Friday, hitting $0.75. 59,513 shares of the company traded hands, compared to its average volume of 2,422,398. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.05. Longeveron has a 1 year low of $0.47 and a 1 year high of $1.23. The stock has a market capitalization of $23.42 million, a price-to-earnings ratio of -0.76 and a beta of -0.31. The business has a 50 day moving average of $0.70 and a two-hundred day moving average of $0.76.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on LGVN shares. Maxim Group lowered Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright cut their target price on Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Monday, May 4th. Weiss Ratings downgraded shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Finally, Wall Street Zen cut Longeveron from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Longeveron currently has a consensus rating of “Hold” and an average price target of $5.50.

Hedge Funds Weigh In On Longeveron

A hedge fund recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new position in shares of Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned approximately 0.32% of Longeveron at the end of the most recent reporting period. 10.01% of the stock is currently owned by institutional investors and hedge funds.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.